LPS-Induced Murine Systemic Inflammation Is Driven by Parenchymal Cell Activation and Exclusively Predicted by Early MCP-1 Plasma Levels  by Juskewitch, Justin E. et al.
The American Journal of Pathology, Vol. 180, No. 1, January 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ajpath.2011.10.001Short Communication
LPS-Induced Murine Systemic Inflammation Is Driven
by Parenchymal Cell Activation and Exclusively
Predicted by Early MCP-1 Plasma LevelsJustin E. Juskewitch,* Bruce E. Knudsen,†
Jeffrey L. Platt,‡ Karl A. Nath,§ Keith L. Knutson,¶
Gregory J. Brunn, and Joseph P. Grande†§
From the Mayo Graduate School,* the Division of Experimental
Pathology,† Department of Laboratory Medicine and Pathology,
the Division of Nephrology and Hypertension,§ Department of
Internal Medicine, and the Departments of Immunology¶ and
Molecular Pharmacology and Experimental Therapeutics, Mayo
Clinic, Rochester, Minnesota; and the Department of Surgery,‡
University of Michigan, Ann Arbor, Michigan
Systemic inflammation remains a major cause of mor-
bidity and mortality in the United States, across many
disease processes. One classic murine model to study
this syndrome is lipopolysaccharide (LPS)–induced
Toll-like receptor 4 (TLR4)–dependent systemic in-
flammation. Although most studies have focused on
inflammatory cell TLR4 responses, parenchymal cells
also express TLR4. Our objective was to define the in
vivo role of parenchymal- versus marrow-derived cell
activation via TLR4 during LPS-induced inflammation.
Mice bearing TLR4 on parenchymal cells only, mar-
row-derived cells only, both, or neither were gener-
ated using bone marrow transplantation. Mortality
occurred only in mice that had TLR4 expression on
their parenchymal cells. Before onset, virtually all
major plasma cytokines and blood neutrophil re-
sponses were related to marrow-derived cell activa-
tion via TLR4. The only cytokine predictive of oncom-
ing systemic inflammation was the chemokine
monocyte chemoattractant protein-1. Late blood neu-
trophil responses were related to the presence of
TLR4 on either parenchymal or marrow cells,
whereas plasma cytokine elevations late in LPS-in-
duced systemic inflammation were dependent on
mice having TLR4 in both cell compartments. Paren-
chymal cell activation via TLR4 is a key component of
LPS-induced systemic inflammation and mortality, al-
though most plasma cytokine levels and blood neutro-
phil responses were not key components. Given its
32unique role, future studies into monocyte chemoattrac-
tant protein-1’s exact role during systemic inflamma-
tion are warranted. (Am J Pathol 2012, 180:32–40; DOI:
10.1016/j.ajpath.2011.10.001)
Systemic inflammation remains a major cause of morbid-
ity and mortality in the United States because it is in-
volved in a host of different infectious and noninfectious
diseases.1–3 One classic animal model for this process is
triggered by lipopolysaccharide (LPS), a Gram-negative
bacterial toxin recognized solely by Toll-like receptor 4
(TLR4).4 The role of TLR4 as the much-sought LPS re-
ceptor was made over a decade ago through the seren-
dipitous discovery of mouse substrains completely resis-
tant to this toxin.5,6 Since then, TLR4 mutant or knockout
mice have been used to study global TLR4 dependence
in a host of other systemic inflammatory diseases.7–9
Investigations into the host systemic inflammatory re-
sponse have focused largely on the actions of inflamma-
tory cells, in part because these cells are easily acces-
sible for study. Responses of these cells to LPS have
been well documented, along with their roles in acute and
chronic tissue injury.10 It is known, however, that TLR4 is
also widely expressed by many different types of paren-
chymal cells.11 It remains unclear what role parenchymal
cell activation via such receptors plays in the pathophys-
iological characteristics of systemic inflammation. Previ-
ous studies12–15 into the roles of these cells in response
to LPS have focused on one particular organ or tissue, as
opposed to the global host response. The objective of
these studies was to determine whether and to what
extent parenchymal cell activation by TLR4 contributes to
LPS-induced systemic inflammation in terms of both early
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philia, organ neutrophil infiltration, and mortality).4 Deter-
mining the kinetics of these changes is key to this inquiry
because some of the most prominent changes could be
the consequence, rather than the cause. Hence, within
the context of these studies, we also tested various cy-
tokines and chemokines early and late in the disease
process to determine which (if any) are crucial to sys-
temic inflammation. Our hypothesis is that systemic in-
flammation is actually driven by parenchymal cell activa-
tion via TLR4 while plasma cytokine levels are driven
instead by marrow-derived cell activation via TLR4.
Materials and Methods
TLR4 Transplantation Mouse Generation
All studies were approved by Mayo Clinic’s institutional
animal care and use committee. Bone marrow transplan-
tations were conducted between C57BL TLR4 wild-type
and/or knockout mice (Jackson Laboratories, Bar Harbor,
ME) using previously published methods.16 In brief, re-
cipient mice were administered neomycin (4 mg/mL in
drinking water) for 24 hours and then irradiated twice
using 5-Gy doses 3 hours apart in a Cs137 irradiator (J.L.
Shepard & Associates, San Fernando, CA). Donor mice
were euthanized, and bone marrow was sterilely ex-
tracted from excised femurs and tibia. Eight million bone
marrow cells, suspended in sterile PBS, were introduced
into each recipient mouse via jugular vein injection under
general anesthesia. Recipient mice continued to receive
4 mg/mL neomycin for 2 weeks, followed by an additional
6- to 8-week recovery period, to reconstitute immunity
with donor bone marrow. Throughout the process, mice
were given standard chow and water ad libitum. In this
manner, two different types of chimeric TLR4 mice, mar-
row TLR4/ (transplant of TLR4/ bone marrow cells
into a TLR4/mouse) and parenchymal TLR4/ (trans-
plant of TLR4/ bone marrow cells into a TLR4/
mouse), along with two types of transplant control mice,
TLR4/ (transplant of TLR4/ bone marrow cells into a
TLR4/ mouse) and TLR4/ (transplant of TLR4/
bone marrow cells into a TLR4/ mouse), were gener-
ated for all experiments. By using this procedure, it was
previously demonstrated that 99% of leukocytes and all
tissue macrophages are replaced from the donor bone
marrow.12,13,16 We confirmed engraftment of donor bone
marrow at 7 weeks after transplantation using the pres-
ence or absence of peripheral blood mononuclear cell
production of tumor necrosis factor (TNF)- in response
to LPS ex vivo (data not shown).
LPS-Induced Systemic Inflammation Model
To induce systemic inflammation, ultra-pure Escherichia
coli LPS (Invitrogen, San Diego, CA) was dissolved in
PBS and injected i.p. To adjust for variations in LPS
biological activity between lots, each lot’s LPS activity
was quantitated using a chromogenic Limulus amoebo-
cyte lysate kit (GenScript, Piscataway, NJ). A dose of
approximately 1.5  1015 endotoxin units per kg wasselected based on pilot studies demonstrating that this
dose achieved systemic inflammation with high mortality
in TLR4/ mice. A matching volume of PBS injected i.p.
was used as a vehicle control.
Survival Curves
Eighteen mice that underwent transplantation (four
TLR4/, five marrow TLR4/, four parenchymal
TLR4/, and five TLR4/) were injected with i.p. LPS
for this experiment. These mice were then monitored for
onset of systemic inflammation and mortality. Murine sys-
temic inflammation induced by LPS was defined as pre-
viously described in a comprehensive review4 of LPS-
induced systemic inflammation in small animals. In brief,
murine LPS-induced systemic inflammation first appears
when mice become: i) less active, ii) disinclined to feed,
and iii) ataxic and weak. At this time, severe neutropenia
also develops. Later in the process, mice become: i) ataxic
and unable to stand; ii) hypothermic; iii) tachypneic, with
labored respirations; and iv) immobilized and unrespon-
sive to stimuli. Mice also develop profuse, fluid diarrhea
and peripheral blood neutrophilia at this point. Mice were
observed by an expert veterinary technician (B.E.K.) who
was blinded to the identity of the groups for up to 10 days
for development of the initial signs of murine LPS-induced
systemic inflammation.
Plasma Cytokines, Blood Neutrophil Content,
and Tissue MPO Content
A total of 65 mice that underwent TLR4 transplantation
(15 TLR4/, 16 marrow TLR4/, 18 parenchymal
TLR4/, and 16 TLR4/) were used for this experiment.
Two thirds of each group received LPS, and one third
received vehicle control, via i.p. injection. For each of
these mice, blood was harvested at 1 hour after injection
for plasma cytokine and blood neutrophil levels. Both
blood and organs (lung, liver, and kidney) were then
harvested at 18 hours, near the time of death, based on
the results of the previous experiment. Signs of murine
systemic inflammation were assessed at 18 hours before
sacrifice using all of the previously defined criteria. For a
subset of these mice, hypothermia was confirmed by
measuring core temperatures via rectal thermometer just
before anesthesia induction for sacrifice. Weights were
recorded before LPS/saline injection and again before
anesthesia induction for sacrifice.
All blood was harvested in 7.5% EDTA. Plasma was
isolated from each blood sample and stored along with
organs at 80°C for analysis. The remaining packed
blood cells were stained using neutrophil marker Gr1-
PerCP at 4°C for 45 minutes (eBiosciences, San Diego,
CA), the red blood cells were lysed, and the remaining
cells were washed and fixed using a whole blood eryth-
rocyte lysing kit (R&D Systems, Minneapolis, MN). Flow
cytometry of the fixed cells was conducted using a BD
FACS Calibur cytometer (BD Biosciences, San Jose, CA).
White blood cells were separated from cellular fragments
using standard forward and side scatter gating. Neutro-
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scatter from the lymphocyte/monocyte population and
then confirmed using the Gr1-PerCP neutrophil marker.
The percentage of neutrophils was calculated using num-
ber of neutrophils/total number of gated white blood cells.
Lung, liver, and kidney myeloperoxidase (MPO) con-
tent was measured using a commercially available mu-
rine MPO enzyme-linked immunosorbent assay kit, as
instructed (HyCult Biotech, Plymouth Meeting, PA).
Plasma cytokines were measured using the Luminex
mouse cytokine 20-plex panel on a Luminex 100
machine, as instructed (Invitrogen, Carlsbad, CA).
IL-13 and monokine induced by gamma interferon
were not considered for these experiments, per Invit-
rogen’s assay validation information, because EDTA
plasma was used.
Statistical Analysis
Kaplan-Meier survival curves were constructed for time to
LPS-induced mortality. Comparisons of curves between
the four TLR4 transplantation groups were conducted
using log-rank testing. LPS-induced plasma cytokine ex-
pression, blood neutrophil levels, and tissue MPO con-
tent were compared across all four TLR4 transplantation
groups initially using one-way analysis of variance and
then the Tukey-Kramer honestly significant differences
test for all subsequent pairwise testing to account for
multiple comparisons. The prediction of oncoming mu-
rine systemic inflammation using 1-hour plasma cytokine
data was assessed using sensitivity, specificity, and area
under the receiver operating characteristic curve. The
95% CIs for sensitivity and specificity were calculated
using the exact binomial method. P  0.05 was consid-
ered statistically significant.
Results
Onset and Mortality
To investigate whether parenchymal- or marrow-derived
cell activation via TLR4 was important to the pathophys-
iological features of systemic inflammation, we first in-
jected LPS into the i.p. space of 18 mice that underwent
transplantation (four TLR4/, five marrow TLR4/, four
parenchymal TLR4/, and five TLR4/). Remarkably,
mortality was entirely dependent on whether TLR4 was
expressed on parenchymal cells (P  0.0004, log-rank
test; Figure 1). TLR4/ mice trended toward having ear-
lier mortality than marrow TLR4/ mice, but this differ-
ence was not significant. In this experiment, murine sys-
temic inflammation started to manifest itself between 2
and 8 hours after injection in the TLR4/ and marrow
TLR4/ mice. No signs of murine LPS-induced systemic
inflammation appeared in the parenchymal TLR4/ and
TLR4/ mice, even up to 10 days after injection (data
not shown).Blood Neutrophil Levels and Distal MPO
Content
To investigate cell compartment roles on neutrophil re-
sponses (neutropenia early and neutrophilia late), we
injected mice that underwent TLR4 transplantation with
LPS or saline vehicle control and measured blood neu-
trophil levels.4 We examined these responses both early
in the process (1 hour after injection), before LPS-in-
duced systemic inflammation had manifested itself, and
again late in the process (18 hours after injection), when
TLR4/ and marrow TLR4/ mice showed signs of
systemic inflammation, but before they died (Figure 1).
We also measured lung, kidney, and liver neutrophilic
activity seen late in murine LPS-induced systemic inflam-
mation by assessing organ MPO content to see the role
such cellular activity has in this process.
In this experiment, 88% of TLR4/, 82% of marrow
TLR4/, 8% of parenchymal TLR4/, and 0% of TLR4/
mice given LPS developed manifestations of murine sys-
temic inflammation by 18 hours (Table 1). There was also
significantly greater weight loss at 18 hours in TLR4/,
marrow TLR4/, and parenchymal TLR4/ mice given
LPS compared with TLR4/ mice given LPS (P  0.001,
one-way analysis of variance; Table 1).
TLR4/ and parenchymal TLR4/mice experienced
significant neutropenia soon after LPS injection com-
pared with marrow TLR4/ and TLR4/ mice (P 
0.0001, one-way analysis of variance; Figure 2A). Late in
the disease process, there was significant neutrophilia in
all mice given LPS, except the TLR4/ mice (P  0.001,
one-way analysis of variance; Figure 2B). Liver MPO con-
tent was significantly elevated at 18 hours after LPS ad-
ministration in TLR4/, marrow TLR4/, and parenchy-
mal TLR4/ mice compared with TLR4/ mice (P 
0.0001, one-way analysis of variance; Figure 2E). More-
over, lung and kidney MPO content at 18 hours after
injection with LPS was significantly elevated in TLR4/
Figure 1. Kaplan-Meier curves for mortality for four groups of mice that
underwent TLR4 transplantation and were given LPS. Four TLR4/, five
marrow TLR4/, four parenchymal TLR4/, and five TLR4/ mice were
used for this experiment. The Kaplan-Meier curves for parenchymal TLR4/
and TLR4/ groups overlap in this figure.and marrow TLR4/mice compared with TLR4/mice,
omplet
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levels (P  0.004 and P  0.0001, respectively; one-way
analysis of variance; Figure 2, C and D).
Early and Late Plasma Cytokine Levels
To further define the role of marrow-derived versus pa-
renchymal cell in the development and progression of
systemic inflammation, we examined early and late
plasma cytokine levels to determine which cytokines, if
any, corresponded to LPS-induced systemic inflamma-
tion (Figure 3 and Figure 4). In terms of early (1 hour after
Table 1. Responses of 65 Mice that Underwent TLR4 Transplant
Injection
Variable
TLR4/ mice
LPS Saline
Total 8 7
LPS-induced systemic inflammation* 7 0
32°C (no./total assessed)† 3/4 0/4
Weight loss (g)‡ 2.0  0.1 0.9  0.3
*Assessed by blinded animal technician based on published descrip
†Rectal temperature assessed before anesthesia administration and c
‡Expressed as mean  SE.injection) plasma cytokine levels before manifestation,
interferon-, IL-1, IL-1, IL-2, IL-4, IL-5, IL-17, granulo-
cyte-macrophage colony-stimulating factor, and vascular
endothelial growth factor were all lower than the detection
threshold of the assay (data not shown). There were no
significant differences in early plasma levels of IL-10 or
IL-12 among any of the groups (data not shown). Both
TNF- and IL-6 elevations corresponded to marrow TLR4
expression but were not associated with oncoming de-
velopment of LPS-induced systemic inflammation (P 
0.0001, one-way analysis of variance; Figure 3, A and B).
Early chemokine levels had a mixture of different expres-
re 2. Blood neutrophil responses at 1 hour (A) and at 18 hours (B)
r injection, along with several organ MPO contents at 18 hours after
ction (C–E) for four groups of mice that underwent TLR4 transplan-
n and were given LPS (black) or saline (white). Fifteen TLR4/, 16
row TLR4/, 18 parenchymal TLR4/, and 16 TLR4/ mice were
for this experiment. Data are represented as the mean  SE. *P 
5 versus TLR4/ mice given LPS; †P  0.05 versus TLR4/ mice
n LPS; ‡P 0.005 versus marrow TLR4/mice given LPS; §P 0.001
us parenchymal TLR4/ mice given LPS.
d Were Given LPS or Saline Vehicle Control at 18 Hours after
row TLR4/
mice
Parenchymal
TLR4/ mice TLR4/ mice
Saline LPS Saline LPS Saline
5 12 6 10 6
0 1 0 0 0
0/3 1/5 0/5 0/2 0/2
0.2 0.0  0.3 2.0  0.2 0.0  0.2 0.8  0.3 0.6  0.3
urine LPS-induced systemic inflammation.4
ed for the last subsets of mice in this experiment.Figu
afte
inje
tatio
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protein (MIP)-1 followed the expression pattern seen in
TNF- and IL-6, whereas keratinocyte chemoattractant
(KC) and interferon gamma-induced protein 10 (IP-10)
plasma levels were elevated in TLR4/, marrow
TLR4/, and parenchymal TLR4/ mice given LPS
compared with TLR4/ mice given LPS (P  0.0001,
one-way analysis of variance; Figure 3, D–F). Of the cy-
tokines and chemokines present, monocyte chemoat-
tractant protein (MCP)-1 followed an expression pattern
that best mirrored oncoming disease (P  0.0001, one-
way analysis of variance; Figure 3C). In fact, 1-hour
MCP-1 plasma levels predicted murine systemic inflam-
mation at 18 hours (Table 1), regardless of their trans-
plant phenotype, with a sensitivity of 100% (95% CI, 84%
to 100%), a specificity of 96% (95% CI, 77% to 100%),
and an area under the receiver operating characteristic
curve of 0.995 (cutoff, 90 pg/mL).
Late (18 hours after injection) plasma cytokine and
chemokine levels followed a consistent expression pat-
tern (Figure 4). IL-1, IL-4, and granulocyte-macro-
phage colony-stimulating factor plasma levels re-
mained lower than the detection threshold of the assay
(data not shown). There was no significant difference in
IL-10 plasma levels among any of the groups (data not
shown). TNF-, IL-1, IL-6, IL-2, IL-12, interferon-,
Figure 3. Plasma levels at 1 hour after injection of TNF- (A), IL-6 (B), MC
TLR4 transplantation and were given LPS (black) or saline (white). Fifteen T
used for this experiment. Data are represented as the mean  SE. The dott
TLR4/ mice given LPS; †P  0.001 versus marrow TLR4/ mice given LPS
TLR4/ mice given LPS.IL-5, IL-17, and vascular endothelial growth factor alldemonstrated the highest plasma levels in TLR4/
mice, with lower or nonexistent levels in the remaining
mice that underwent transplantation and were given
LPS (P  0.0005, one-way analysis of variance; Figure
4, A–H; vascular endothelial growth factor data not
shown). Plasma chemokine levels (MCP-1, KC, MIP-1,
and IP-10) also reflected this expression pattern
among the groups given LPS (P  0.001, one-way
analysis of variance; Figure 4, I–L).
Discussion
These data suggest that parenchymal cell activation via
TLR4 drives mortality from murine LPS-induced systemic
inflammation (Table 2). At most, marrow-derived cell ac-
tivation via TLR4 may play a role in accelerating LPS-
induced systemic inflammation. These overall findings
seem consistent with previous observations of isolated
organ systems using chimeric TLR4 mice, in that paren-
chymal TLR4 drives both neutrophilic sequestering into
the lungs during LPS-induced inflammation and leuko-
cyte recruitment to the brain after intracranial LPS injec-
tion.12,15 Interestingly, parenchymal TLR4 expression did
not cause mortality in a Gram-negative infection model
(E. coli peritonitis). This could be because of the multifac-
KC (D), MIP-1 (E), and IP-10 (F) for four groups of mice that underwent
16 marrow TLR4/, 18 parenchymal TLR4/, and 16 TLR4/ mice were
indicates the minimal-detectable threshold for the assay. *P  0.005 versus
.05 versus marrow TLR4/ mice given LPS; §P  0.005 versus parenchymalP-1 (C),
LR4/,
ed line
‡eted host responses that compose an effective systemic
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AJP January 2012, Vol. 180, No. 1Figure 4. Plasma levels at 18 hours after injection of TNF- (A), IL-1 (B), IL-6 (C), IL-2 (D), IL-12 (E), interferon (IFN)- (F), IL-5 (G), IL-17 (H), MCP-1 (I), KC
(J), MIP-1 (K), and IP-10 (L) for four groups of mice that underwent TLR4 transplantation and were given LPS (black) or saline (white). Fifteen TLR4/, 16
/ / /marrow TLR4 , 18 parenchymal TLR4 , and 16 TLR4 mice were used for this experiment. Data are represented as the mean SE. The dotted line indicates
the minimal-detectable threshold for the assay. *P  0.005 versus marrow TLR4/, parenchymal TLR4/, and TLR4/ mice given LPS.
ate no
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duced systemic inflammation.17
Circulating and tissue-bound neutrophils are believed
to be significant contributors to tissue damage during the
systemic inflammatory response. We found that early
neutropenia is related to marrow-derived cell TLR4 ex-
pression, suggesting that TLR4 activation of these cells
instead induces early neutrophilic margination and ex-
travasation (Figure 2A). Later in the disease process,
TLR4 activation of parenchymal and/or marrow-derived
cells leads to increased bone marrow release of neutro-
phils (Figure 2B). In terms of end-organ neutrophilic ac-
tivity (as assessed by MPO content), lung and kidney
neutrophilic activity levels were highest in the TLR4/
and marrow TLR4/ mice given LPS and had lower
elevations in the parenchymal TLR4/ mice given LPS
(Figure 2, C and D). These findings appear more consis-
tent with the pattern of LPS-induced murine systemic
inflammation observed in the TLR4/ and marrow
TLR4/ mice. This pattern in lung and kidney MPO is
consistent with previous research12,15 involving chimeric
TLR4 mice, which suggested that neutrophil rolling and
margination in the brain and lung in response to LPS were
solely driven by parenchymal TLR4. However, the differ-
ences between TLR4/, marrow TLR4/, and paren-
chymal TLR4/ organ MPO content are not as striking
as the differences in LPS-induced murine systemic in-
flammation, mortality, and blood neutrophil responses
(Table 2 and Figures 1 and 2). Based on these consid-
erations, we suggest that it is likely that activation of either
cellular compartment via TLR4 helps drive the entry
and/or activation of neutrophils in these organs, but neu-
trophil activity’s relationship to the actual manifestations
of systemic inflammation may be far more complicated.
This pattern of MPO content and TLR4 expression in any
cellular compartment is seen more robustly in the liver.
This starker effect may be because of intrinsic differ-
ences in liver architecture, where capillary endothelial
structure is fenestrated, allowing easier organ access
from the vasculature. Neutrophilic activation could then
be driven by blood neutrophil responses (late neutro-
philia) as much as end-organ TLR4 activation.
Given the known functions of cytokines and chemo-
Table 2. Summary of Experimental Results for LPS-Induced Syst
Variable TLR4/ mice Mar
Systemic inflammation and mortality X
Early cytokines
TNF-, IL-6, MIP-1 X
KC, IP-10 X
MCP-1 X
Early neutropenia X
Weight loss X
Late cytokines X
Late neutrophilia X
Organ MPO
Lung, kidney X
Liver X
The blank spaces in this table (e.g., under TLR4-/- mice column) indic
X, differences compared with saline control mice.kines in the systemic inflammatory response, we nextexplored whether these mediators were connected to the
pattern of LPS-induced systemic inflammation and sub-
sequent mortality. The nearly complete disconnect we
observed between early plasma cytokine levels and
signs of LPS-induced systemic inflammation is surpris-
ing. These data indicate that most early cytokine produc-
tion is marrow-derived cell in origin. This is consistent
with previously described sources of these mediators.
However, classic pro-inflammatory acute-phase cyto-
kines (TNF- and IL-6) drive hepatic acute-phase protein
synthesis, endothelial cell activation, leukocyte extrava-
sation, and shock, consistent with Koch’s postulates.18
Yet, we observed high plasma levels of these mediators
in one group of chimeric TLR4 mice (parenchymal
TLR4/) with intact cytokine signaling pathways that did
not develop signs of systemic inflammation and much
lower plasma levels of these mediators in another group
of chimeric TLR4 mice (marrow TLR4/) that did de-
velop signs of systemic inflammation (Table 1 and Figure
3). Given the initial interest in these pro-inflammatory
cytokines based on models such as LPS-induced sys-
temic inflammation, our results may help to explain their
failure as diagnostic and therapeutic targets in the clinic
because their role in a classic model of systemic inflam-
mation may not be as crucial as once thought.19–21 Fur-
ther studies are needed to define mechanisms by which
TLR4 signaling within parenchymal cells drives the actual
manifestations of systemic inflammation.
The one early plasma cytokine found to have clear
prognostic value was MCP-1 (chemokine ligand 2).
MCP-1 is a chemokine that attracts monocytes, mast
cells, and basophils to the sites of inflammation and can
be produced by both immune and nonimmune cells.22–24
Plasma MCP-1 has been elevated in response to LPS in
mice, baboons, and humans, although the nature of its
role in this systemic inflammatory response is un-
clear.25,26 Previous reports27,28 of MCP-1 blockade in
murine LPS-induced systemic inflammation have demon-
strated both protective and detrimental effects, leading to
no definitive conclusion. Although the studies presented
herein cannot yet address MCP-1’s exact role (neutral,
beneficial, or harmful), it is clear that its role in the devel-
opment of LPS-induced systemic inflammation and sub-
flammation in Mice that Underwent TLR4 Transplantation
R4/ mice Parenchymal TLR4/ mice TLR4/ mice
X
X
X X
X
X
X X
X X
X
X X
difference compared with saline control mice.emic In
row TLsequent mortality may be unique compared with other
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gated. It is well established that MCP-1 cannot initiate a
systemic inflammatory response when introduced into
mice, suggesting a more indirect role in this disease
process.29–32 Given the morbidity and mortality associ-
ated with systemic inflammation in many disease pro-
cesses, the value of a plasma molecule predictive of
oncoming systemic inflammation clinically would be im-
mense, especially in those situations in which the
development of systemic inflammation occurs only in a
subset of patients, regardless of its exact function in the
process.10,33,34
Even late in LPS-induced systemic inflammation,
plasma cytokine profiles continue to be disassociated
with present status (Table 1 and Figure 3). Globally,
plasma cytokines in the TLR4/ mice seem to show an
additive or synergistic relationship between marrow-de-
rived cell and parenchymal cell activation during LPS-
induced systemic inflammation. However, late plasma
cytokine levels (TNF-, IL-1, IL-6, IL-5, IL-10, MCP-1,
KC, and MIP-1) remained indistinguishable (or unde-
tectable) in the two chimeric TLR4 mouse groups (mar-
row TLR4/ and parenchymal TLR4/), even though
these two groups have fundamentally different responses
to LPS. What this may suggest is that late in the systemic
inflammatory disease process, plasma cytokines and
chemokines may drive a more rapid course for systemic
inflammation, as suggested in Figure 1.
In summary, our findings indicate that expression of
TLR4 by parenchymal cells is primarily responsible for
the development of LPS-induced systemic inflammation
and subsequent mortality. In this model, both early and
late blood neutrophil responses and plasma cytokine lev-
els do not predict the development of systemic inflam-
mation, even though exogenous administration of cyto-
kines, such as TNF- in wild-type mice (capable of
signaling via TLR4 in both parenchymal and bone mar-
row–derived cells), can produce systemic inflammation
via NF-B activation.35
Our study has several limitations that need to be ad-
dressed in future studies. First, our definition of systemic
inflammation depends primarily on clinical observation.
Although the onset of systemic inflammation was associ-
ated with mortality, the timing of systemic inflammation
onset could be more precise through regular assessment
of heart rate, respiratory rate, and temperature. Although
TLR4 signaling in parenchymal cells drives the develop-
ment of LPS-induced systemic inflammation, our data
suggest that marrow-derived cell activation via TLR4 may
accelerate or exacerbate an already initiated systemic
inflammatory process. MCP-1 was unique in its expres-
sion pattern early and was the only chemokine to predict
the onset of LPS-induced systemic inflammation with high
accuracy. Given that exogenous administration of MCP-1
does not produce systemic inflammation in experimental
animals, the mechanistic role of MCP-1 in this process
awaits further clarification.29–32 The parenchymal cell
source of MCP-1 has not yet been defined. These studies
are important because existing studies of the role of
MCP-1 in preventing or exacerbating host systemic in-
flammatory responses to LPS are contradictory. Finally,our experimental model, which segregates TLR4 activa-
tion in parenchymal cells and bone marrow–derived
cells, may be regarded as artificial, in that TLR4 signaling
in both compartments is intact during human systemic
inflammation. Nevertheless, this model may shed mech-
anistic insights related to TLR4 signaling in systemic in-
flammation; further studies with this model may help us
understand why plasma chemokine levels often fail to
predict outcome during systemic inflammation pro-
cesses.
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